12:00 AM
 | 
Apr 24, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Xeloda capecitabine: Phase II data; sNDA under review; marketed to treat metastatic breast cancer

Roche published in the Journal of Clinical Oncology that in a 108-patient 48-week Phase II trial, partial or complete responses were seen in 21-24 percent...

Read the full 101 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >